Estrella Immunopharma Inc (ESLA)

$1.26 -0.01 (-0.79%)
Market Cap 54.19M
Revenue (ttm) 0.00
Net Income (ttm) -13.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 42,800
Avg Vol 98,998
Day's Range N/A - N/A
Shares Out 42.67M
Stochastic %K 9%
Beta 0.97
Analysts Strong Sell
Price Target $10.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
BecauseOfScout
BecauseOfScout Apr. 8 at 3:54 PM
$ESLA Registered warrants at $1.39 making it hard for this to move up further. Heavy supply of located available — when’s the PR? Asking for a friend…
0 · Reply
Arcides
Arcides Apr. 7 at 9:45 PM
$BMEA $ESLA $PRLD on fire
0 · Reply
Soyaz
Soyaz Apr. 7 at 3:06 PM
$ESLA
0 · Reply
neangewo
neangewo Apr. 6 at 5:21 PM
$ESLA Up on big volume and no news! Took a starter for a swing!
0 · Reply
ZacksSCR
ZacksSCR Mar. 26 at 8:39 PM
CAR-T therapy has reshaped oncology, but toxicity and durability remain challenges. $ESLA's ARTEMIS® platform is built to address both. Zacks SCR initiates coverage with early STARLIGHT-1 data showing a 100% CR rate at dose level 2. #CARTCell #Biotech #Oncology #SmallCap https://youtu.be/JoD4rNMoY-s
1 · Reply
ZacksSCR
ZacksSCR Mar. 18 at 1:23 PM
$ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T https://buff.ly/hJfckaA
0 · Reply
BonjerminFranklin
BonjerminFranklin Mar. 6 at 2:07 PM
$ESLA wtf happen😂.. another rinse and repeat moment!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 1:02 AM
$ESLA RSI: 21.78, MACD: -0.0183 Vol: 0.10, MA20: 1.24, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 10:22 PM
$ESLA Current Stock Price: $1.18
0 · Reply
Pb1782
Pb1782 Feb. 13 at 3:43 PM
$ESLA
0 · Reply
Latest News on ESLA
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

May 5, 2026, 8:00 AM EDT - 4 days ago

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Mar 23, 2026, 8:00 AM EDT - 6 weeks ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

Estrella Immunopharma presents updated data on EB103

2026-02-09T12:21:27.000Z - 3 months ago

Estrella Immunopharma presents updated data on EB103

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 9, 2026, 7:00 AM EST - 3 months ago

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 3, 2026, 8:00 AM EST - 3 months ago

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Jan 6, 2026, 2:02 PM EST - 4 months ago

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Jan 5, 2026, 8:30 AM EST - 4 months ago

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma files to sell 2.54M shares of common stock for holders

2025-12-22T16:00:22.000Z - 4 months ago

Estrella Immunopharma files to sell 2.54M shares of common stock for holders

Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review

2025-12-04T13:15:12.000Z - 5 months ago

Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Dec 4, 2025, 8:00 AM EST - 5 months ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial

2025-11-03T13:10:26.000Z - 6 months ago

Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 6 months ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma regains compliance with Nasdaq

2025-10-06T12:11:06.000Z - 7 months ago

Estrella Immunopharma regains compliance with Nasdaq

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma announces additional site for STARLIGHT-1 trial

2025-06-05T12:31:13.000Z - 1 year ago

Estrella Immunopharma announces additional site for STARLIGHT-1 trial

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement

2025-06-03T12:20:42.000Z - 1 year ago

Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial

2025-05-29T12:10:26.000Z - 1 year ago

Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 1 year ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma completes first dose cohort in STARLIGHT trial

2025-02-21T13:55:36.000Z - 1 year ago

Estrella Immunopharma completes first dose cohort in STARLIGHT trial

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 1 year ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma initiated with a Buy at D. Boral Capital

2025-02-18T12:16:45.000Z - 1 year ago

Estrella Immunopharma initiated with a Buy at D. Boral Capital

Estrella Immunopharma files $100M common stock, warrants offering

2024-12-12T22:15:11.000Z - 1 year ago

Estrella Immunopharma files $100M common stock, warrants offering

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma names Hong Zhang as chairperson

2024-08-14T16:01:35.000Z - 1 year ago

Estrella Immunopharma names Hong Zhang as chairperson

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

BecauseOfScout
BecauseOfScout Apr. 8 at 3:54 PM
$ESLA Registered warrants at $1.39 making it hard for this to move up further. Heavy supply of located available — when’s the PR? Asking for a friend…
0 · Reply
Arcides
Arcides Apr. 7 at 9:45 PM
$BMEA $ESLA $PRLD on fire
0 · Reply
Soyaz
Soyaz Apr. 7 at 3:06 PM
$ESLA
0 · Reply
neangewo
neangewo Apr. 6 at 5:21 PM
$ESLA Up on big volume and no news! Took a starter for a swing!
0 · Reply
ZacksSCR
ZacksSCR Mar. 26 at 8:39 PM
CAR-T therapy has reshaped oncology, but toxicity and durability remain challenges. $ESLA's ARTEMIS® platform is built to address both. Zacks SCR initiates coverage with early STARLIGHT-1 data showing a 100% CR rate at dose level 2. #CARTCell #Biotech #Oncology #SmallCap https://youtu.be/JoD4rNMoY-s
1 · Reply
ZacksSCR
ZacksSCR Mar. 18 at 1:23 PM
$ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T https://buff.ly/hJfckaA
0 · Reply
BonjerminFranklin
BonjerminFranklin Mar. 6 at 2:07 PM
$ESLA wtf happen😂.. another rinse and repeat moment!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 1:02 AM
$ESLA RSI: 21.78, MACD: -0.0183 Vol: 0.10, MA20: 1.24, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 10:22 PM
$ESLA Current Stock Price: $1.18
0 · Reply
Pb1782
Pb1782 Feb. 13 at 3:43 PM
$ESLA
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 4:21 AM
$ESLA Current Stock Price: $1.42
0 · Reply
ZacksSCR
ZacksSCR Feb. 9 at 7:04 PM
$ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL https://buff.ly/zdOT8JR
0 · Reply
neangewo
neangewo Feb. 9 at 12:40 PM
$ESLA PR is out and the headline could not be any better! Will the price run up though? We shall see.
0 · Reply
neangewo
neangewo Feb. 9 at 1:54 AM
$ESLA PR AM tomorrow?
0 · Reply
BonjerminFranklin
BonjerminFranklin Feb. 6 at 10:01 PM
$ESLA wtf!? 😂
1 · Reply
stinstewart
stinstewart Feb. 6 at 7:17 PM
$ESLA big volume
0 · Reply
stinstewart
stinstewart Feb. 6 at 7:16 PM
$ESLA news already out? Nasdaq: ESLA today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The presentation will highlight clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). Estrella’s late-breaking abstract will be available on February 4, 2026, at 12:00 a.m. CT, via the conference website at www.tandemmeetings.com. Details of the Late-Breaking Oral Presentation: · Final Paper Number: LBA-1 · Abstract ID & Title: 29644: Phase-1 Study of CD19-ARTEMIS T Cells (EB103) in Patients with Aggressive B-Cell · Session Date/Time: Saturday, February 7, 2026, 3:15 p.m. MST · Presenting Author: Naseem Esteghamat, MD MS
0 · Reply
neangewo
neangewo Feb. 6 at 4:49 PM
$ESLA So much for positive momentum before their late breaker presentation tomorrow!
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 6 at 4:40 PM
$ESLA RSI: 50.48, MACD: -0.0822 Vol: 0.10, MA20: 1.05, MA50: 1.43 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply